At Rush University Medical Center, we are putting your safety first. For information about COVID-19, see the latest updates. Rush accepts donations to support our response effort, staff, and patients and families.

Excellence is just the beginning.


French German Italian Portuguese Russian

Cellular Autoimmune Mechanisms of Narcolepsy Study

Clinical Trial Title: 
Study on the cellular autoimmune mechanisms of narcolepsy.
Clinical Trial Protocol ID: 
Clinical Trial Investigator Name: 
Igor J. Koralnik, MD
Clinical Trial Protocol Description: 

The purpose of this study is to determine whether narcolepsy patients with cataplexy exhibit an autoimmune response against the peptide orexin, which is depleted in this condition. A blood sample of 30 mL (about 2 tablespoons) will be taken to measure the participant’s cellular immune response against orexin. Subjects will also be tested for a DQB1 allele that is strongly linked to narcolepsy with cataplexy.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Are at least 6 years of age.

You will be excluded from the study if any of the following criteria apply to you:

  • Have narcolepsy without cataplexy.
  • Have a sleep disorder other than narcolepsy.

This is a partial list of inclusion and exclusion criteria.

Clinical Trial Area: 
Neurological Disorders
Contact Phone: 
(312) 563-7317 or (312) 563-7304
Contact Name: 
Dom Tucker or Zack Orban